Description
Product Usage Information
SignalFlex™ conjugates are produced using highly validated Cell Signaling Technology ® primary antibodies and conjugation methods that have been rigorously tested, ensuring high-quality conjugates and lot-to-lot consistency. These conjugates are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity. However, they are not tested on specific assays. Optimal dilutions/concentrations should be determined by the end user. When performing flow cytometry, we recommend using an isotype control conjugate at the same concentration as the antibody conjugate.
Storage
Supplied in PBS (pH 7.2), less than 0.1% sodium azide, and 2 mg/mL BSA. Store at 4°C. Do not aliquot the antibody. Protect from light. Do not freeze.
Specificity / Sensitivity
Phospho-Pyruvate Dehydrogenase α1 (Ser293) (E4V9L) Rabbit mAb (SignalFlex™ Alexa Fluor
Species Reactivity: Human, Mouse, Rat, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Ser293 of human pyruvate dehydrogenase α1 protein.
Background
The pyruvate dehydrogenase complex catalyzes the conversion of pyruvate and CoA into acetyl-CoA and CO in the presence of NAD . Acetyl-CoA then goes into the citric acid cycle where it reacts with oxaloacetate to form citrate. The reaction of oxidative decarboxylation of pyruvate serves as a critical link between glycolysis and the citric acid cycle. In mammalian cells, the pyruvate dehydrogenase complex is located in the mitochondrial matrix (1). This complex is composed of three enzymes: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2), and dihydrolipoamide dehydrogenase (E3). Pyruvate dehydrogenase (E1) consists of two subunits: α and β. This enzyme catalyzes the removal of CO from pyruvate. Mutations in the α subunits of pyruvate dehydrogenase (E1) lead to congenital defects that are usually associated with lactic acidosis, neurodegeneration, and early death (2). Pyruvate dehydrogenase kinase 1 phosphorylates pyruvate dehydrogenase (E1) α1 subunit at Ser293 to inactivate its activity (3,4). This phosphorylation contributes to the tumor metabolic reprogramming toward glycolysis in hypoxia by inhibiting the citric acid cycle (4).
Alternate Names
MGC149517; MGC149518; ODPA; ODPAT; PDHA; PDHA1; PDHA2; PDHAD; PDHAL; PDHCE1A; PDHE1-A type I; PDHE1-A type II; PHE1A; pyruvate dehydrogenase (lipoamide) alpha 1; pyruvate dehydrogenase (lipoamide) alpha 2; pyruvate dehydrogenase alpha 1; pyruvate dehydrogenase alpha 2; pyruvate dehydrogenase complex, E1-alpha polypeptide 1; pyruvate dehydrogenase E1 alpha 1; pyruvate dehydrogenase E1 alpha 1 subunit; pyruvate dehydrogenase E1 alpha 2; pyruvate dehydrogenase E1 alpha 2 subunit; Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial; Pyruvate dehydrogenase E1 component subunit alpha, testis-specific form, mitochondrial; pyruvate dehydrogenase E1 subunit alpha 1; pyruvate dehydrogenase E1 subunit alpha 2; pyruvate dehydrogenase, E1-alpha polypeptide, testis specific
